The Latest Breaking News from Merck

The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Mar 31, 2022

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Mar 29, 2022

EMA's Advisory Group Backs Approval For Merck's Keytruda In Various Cancer Settings

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Merck & Co Inc (NYSE: MRK) for 

Benzinga · Mar 25, 2022

A doctor takes on Big Pharma

In “Sickening,” Harvard professor John Abramson chronicles the deceptive marketing practices of the drug industry

Salon · Mar 20, 2022

Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients

Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC).

Benzinga · Mar 15, 2022

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Mar 15, 2022

Two years into the pandemic, unequal access to COVID-19 treatments threatens the global recovery

It’s now two years since the World Health Organization began calling the COVID-19 outbreak a pandemic.

The Conversation · Mar 13, 2022

Fears over drug used to treat Covid and link to serious birth defects

One expert says similar drugs have been shown to cause animals to be born with no teeth or parts of skull missing

Wales Online · Mar 9, 2022

Molnupiravir: why are there potential safety issues around this COVID antiviral?

If you’re worried about COVID, there’s a simple way to boost protection: get vaccinated. But this doesn’t work for everyone. People with weak immune systems – perhaps because of age or a medical condition – don’t respond well to vaccines. For them, COVID still poses a significant risk.

The Conversation · Mar 8, 2022

Why Alpine Immune's Shares Are Falling Today

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ:ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies. The partial clinical hold was prompted by Alpine's report of patient death in the NEON-2 trial.  The participant had choroidal melanoma previously treated with nivolumab and…

Benzinga · Mar 7, 2022